ST. LOUIS (KMOV) -A clinical trial at the Washington University School of Medicine is studying the impact of an antidepressant on long COVID symptoms.
Specifically, the study is examining whether Fluvoxamine, a medication used to treat depression and obsessive-compulsive disorder, can relieve problems with “brain fog” and other neurological conditions associated with lingering symptoms.
The latest article on the Healthy minds lab study on how fluvoxamine can help treat and prevent sever COVID-19 symptoms.
Another article describing Andrea Fekete and Eric Lenses findings on fluvoxamine’s efficacy against fighting the worst of the COVID symptoms. The article describes the way fluvoxamine allows for the body’s inflammatory system to keep in check due to the presence of the sigma-1 receptor.
CNN’s discussion on the latest study that found that fluvoxamine could reduce the risk of having severe COVID-19 symptoms. “Fluvoxamine may reduce the production of inflammatory molecules called cytokines that can be triggered by SARS-COV-2 infection.”
This is the first large and randomized controlled trial test to test the efficacy of fluvoxamine for acute treatment of COVID-19. In the study, they found an absolute risk reduction of 5.0% and a 32% RR reduction.
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial Eric J. Lenze, MD1; Caline Mattar, MD2; Charles F. Zorumski, MD1; Angela Stevens, BA1; Julie Schweiger1; Ginger E. Nicol, MD1; J. Philip Miller, AB3; Lei Yang, MPH, MSIS1; Michael Yingling, MS1; Michael S. Avidan, MBBCh4; Angela M. Reiersen, MD, MPE1JAMA. Published online November 12, 2020. doi:10.1001/jama.2020.22760
